The fourteen-day problem, and what it does to a commercial testing model
Endotoxin is the more tractable of the two questions, and a kinetic chromogenic determination is neither slow nor exotic. It is simply not on the menu.
Harriet Oduya
Page 9 of 10 of this archive, newest first.
Archive — page 9
192 piecesIndependent analysis puts a QYB mazdutide lot at 95.1%, against 91.4% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The question no chromatogram has ever answered
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
SUSTAIN-6 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a WWB survodutide lot at 99.2%, against 95.5% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
The lead-in, the randomisation, and the year that followed
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
PeptideMeter result on a Changsha liraglutide lot lands 3.8 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
What STEP 4 tells us about maintenance, and what it does not
The commonest real-world strategy in this drug class is the least studied one.
STEP 4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Manual reintegration is legitimate, and it should be declared
We work through a single chromatogram twice, under two integration conventions, and show where the difference comes from.
SURMOUNT-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What happens when the drug is taken away: three randomised answers
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Grams per kilogram of what? The denominator problem in protein guidance
The practical difficulty is not knowing the target. It is meeting it on an appetite that has been pharmacologically reduced by half.
Twenty-eight days is a number from somebody else’s product
We set out what is known, what is inferred and what is simply assumed about the fortnight after a vial is opened.
VendorInvestigate result on a Hong Kong mazdutide lot lands 2.6 points below the supplier’s figure
The result is unremarkable. What the report omits is not.